After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...

Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.

All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment ...

Pfizer has announced the withdrawal of all lots of OXBRYTA approved for treating sickle cell disease (SCD) from worldwide ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...